Gynae problems Flashcards
PMB: overall risk of underlying endometrial Ca
10%
PMB >80yo: risk of underlying endometrial ca
25%
PMB<50yo: risk of underlying endometrial ca
1%
PMB + obesity: risk of underlying endometrial ca
18%
PMB + diabetes: risk of underlying endometrial ca
21%
PMB + obesity + diabetes: risk of underlying endometrial ca
29%
most common cause of PMB
atrophic endometritis and vaginitis (60-80%)
progression rate of EH without atypia (overall)
<5% over 20 y
progression rate of SIMPLE EH without atypia
1%
progression rate of COMPLEX EH without atypia
4%
progression rate of EH WITH ATYPIA
27% over 20y
prevalence of atypia within endometrial polyp
0.8% -1.2% in asymptomatic patient (up to 2%)
prevalence of malignancy within endometrial polyps
3.1% in symptomatic patients (only 0.3% in asymptomatic)
EH without atypia: rate of REGRESSION
75-80%
vaginal discharge following UAE
20-30%
16% at 12/12
expulsion of fibroid material following UAE
10%
endometritis following UAE
0.5%
change in sexual fxn following UAE
worse 10%
improved 26%
unchanged in most
early ovarian failure following UAE
1-2%
UAE is associated with higher rates of ____ intrapartum
C/S
PPH
GnRH for fibroids: % reduction in size at 12 weeks
36%
GnRH for fibroids: fibroid size returned to pre-treatment within ____
4-6 months
pre-test probability of Endometrial ca in TVS ET<4mm
<1%
systemic HRT benefits
sx control BMD maintenance decreased CAD and alzheimers if started early decreased colorectal ca decreased T2DM
systemic HRT risks
endometrial ca VTE (2-3x background risk) CHD - if started >60yo stroke Breast ca - slight increase after 5y small but not significant increase ovarian ca
combined systemic HRT: impact on breast ca risk
increase by 4/1000 cases
oestrogen only systemic HRT: impact on breast ca risk
decrease by 4/1000 cases
prevalence of PMS
40%
severe PMS incidence
5-8%
first line management PMS
Exercise
CBT
Vit B6
COCP (continuous or cyclical - ideally containing drosperinelone eg Yasmin)
Continuous or luteal phase low dose SSRI (eg. citalopram 10mg)
Second line management PMS
estradiol patches 100mcg + micronised progesterone day 17-28 (or LNG-IUS)
Higher dose SSRIs (20-40mg)
third line management PMS
GnRH analogues + add back HRT
- reserve for most severe sx
- *need DEXA annual
post menopausal simple cyst <5cm: at 2y, what proportion disappear
53%
post menopausal simple cyst <5cm: at 2y, what proportion remain static
28%
post menopausal simple cyst <5cm: at 2y, what proportion increase in size
11%
post menopausal simple cyst <5cm: at 2y, what proportion decrease in size
3%
post menopausal simple cyst <5cm: at 2y, what proportion fluctuate
6%
post menopausal simple cyst <5cm, asymptomatic, unilateral, unilocular, normal Ca125 – MANAGEMENT? Risk of malignancy?
Ca125 and Repeat USS in 4-6/12 x 1y
Discharge at 1y if no change
Risk of malignancy <1%
RMI<25 – % risk malignancy?
<3%
RMI 25-250 – % risk malignancy?
20%
RMI >250 – % risk malignancy?
75%
pre-menopause ovarian cyst - lifetime risk
10%
pre-menopause ovarian cyst - % borderline appearing as simple cyst
20%
pre-menopause ovarian cyst: management of asymptomatic simple cyst <5cm
discharge, likely physiological
pre-menopause ovarian cyst: management of asymptomatic simple cyst 5-7cm
year USS +/- MRI +/- surgery
pre-menopause ovarian cyst: management of asymptomatic simple cyst >7cm
MRI
risk of recurrence ovarian cyst if aspirated
53-84%
risk of chemical peritonitis if dermoid spillage
0.2%
incidence of malignant symptomatic cyst (pre-menopause)
1/1000
differentiated VIN associated with ____
lichen sclerosus
undifferentiated VIN associated with ____
HPV and smoking
rate of re-operation for recurrent menstrual symptoms following endometrial ablation
20-27%
Lower rates with 2nd gen techniques, but not statistically significant
Saraswat, L, Cooper, K. Surgical management of heavy menstrual bleeding: part 1. The Obstetrician & Gynaecologist 2017; doi:10.1111/tog.12333 19: 37– 45.
rate of hysterectomy for recurrent menstrual symptoms following endometrial ablation
14-20% by 5y
Majority will occur within 2y
Saraswat, L, Cooper, K. Surgical management of heavy menstrual bleeding: part 1. The Obstetrician & Gynaecologist 2017; doi:10.1111/tog.12333 19: 37– 45.
re-intervention rate for UAE at 3y
15%
hysterectomy rate after UAE at 5y
28%
incidence of OAB
13-16%
proportion requiring additional management after salpingotomy
1/5
overall survival cervical cancer
65% (65-70%)
cervical cancer stage I survival
95%